Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 13/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798268 | 0.90 | HSD17B3 (0.59) | HSD17B3KDM4ENPC1RAB9ANOTUM | |
| SCHEMBL4799403 | 0.88 | HSD17B3 (0.57) | HSD17B3NAMPTNOTUM | |
| SCHEMBL4800970 | 0.86 | HSD17B3 (0.63) | HSD17B3HTTSMN1; SMN2NAMPTKDM4E | |
| SCHEMBL4796728 | 0.83 | HSD17B3 (0.56) | HSD17B3HTTSMN1; SMN2NAMPTKDM4E | |
| SCHEMBL4796722 | 0.83 | HSD17B3 (0.56) | HSD17B3HTTSMN1; SMN2NAMPTKDM4E | |
| SCHEMBL4800848 | 0.77 | HSD17B3 (0.61) | HSD17B3NOTUM | |
| SCHEMBL21172654 | 0.74 | HTT (0.52) | HTTSMN1; SMN2NAMPTKDM4ENPC1 | |
| SCHEMBL21172961 | 0.74 | HTT (0.52) | HTTSMN1; SMN2NAMPTKDM4ENPC1 | |
| SCHEMBL4048444 | 0.74 | HSD17B3 (0.71) | HSD17B3NOTUM | |
| SCHEMBL4800410 | 0.74 | HSD17B3 (0.75) | HSD17B3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HSD17B3 1/4885HTT 2984/4885SMN1; SMN2 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.